Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo: Focus on 2005 - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Mar 24, 2004

    Glaxo: Focus on 2005

    GlaxoSmithKline India is a 41% subsidiary of world's second largest pharmaceutical company, GlaxoSmithKline Pharmaceuticals Plc. - UK, which has a sales turnover of US$ 27 bn. In Indian market, Glaxo is the largest player with 5.6% share of the Indian pharma market and has been the undisputed leader for the last 27 years. The company has a wide drug portfolio and caters to different therapeutic segments. Augmentin - a brand owned by the company has consistently been the No. 1 vaccine in the domestic market. The company has three manufacturing facilities at Thane, Nashik and Mysore. Glaxo has a very strong field presence with a good brand recall amongst doctors. The strong presence in the field makes it strong competitor in the Indian domestic pharma markets.

    Glaxo has grown (more or less) in line with the growth in the pharmaceutical industry. Revenue growth shows a CAGR of 7.7% over the last five years while profits have clocked a 22% CAGR. The following graph illustrates the same.

    Owing to the process patent regime prevalent in India, Glaxo shied away from introducing new drugs from its parent's product stable. Hence, its product folio has become old and faces stiff price competition from the local Indian companies in therapeutic categories it operates in. The company's pharmaceutical business constitutes 81% of revenues, while animal healthcare and chemical business constitutes the remaining 19%.

    With new patent regime coming into effect from January 1st, 2005 the company is gearing itself for the opportunities that will unfold. With product patent regime it is very much likely that the parent company will introduce new chemical entities, which will considerably strengthen the product portfolio of the company in the market. Also, the parent may also look at the company as a major hub for outsourcing several bulk drugs. Glaxo is already making base (raw material) for Ranitidine and exporting it to the parent.

    Glaxo is in advanced stages of negotiations for its Worli property in Mumbai, which is expected to give its extraordinary income a fillip in FY05. The company is gearing itself towards 2005, when the patent regime comes into force. It has also finalised the much awaited merger with Burroughs Wellcome. The merger ratio has been fixed at 10:14 (for every 14 shares of Burroughs, shareholders will get 10 shares of Glaxo). At the current price of Rs 579, the stock is trading at a P/E of 25x FY04 earnings. The company has declared a dividend of Rs 10 per equity share for FY04 (Rs 7 in FY03). Though the valuations seem at the upper end of the spectrum, future benefits during the patent regime post 2005, as well as expectations of an extra-ordinary income is keeping the investor interest alive.



    Equitymaster requests your view! Post a comment on "Glaxo: Focus on 2005". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Quarterly Results With Charts